Rethinking the Use of Biologics in Inflammatory Bowel Disease Patients With Malignancy: Insights From the Treatment of Immune Checkpoint Inhibitor-Induced Colitis
Lay Summary Managing inflammatory bowel disease in cancer patients is challenging due to concerns about biologics’ effects on malignancy. Recent evidence suggests a low risk of cancer progression, but data gaps persist. Research on immune checkpoint inhibitor-induced colitis and biologic safety remains limited.
Authors
- Marco Vincenzo Lenti (ORCID: https://orcid.org/0000-0002-6654-4911)
- Giovanni Santacroce (ORCID: https://orcid.org/0000-0002-0544-0414)
- Antonio Di Sabatino (ORCID: https://orcid.org/0000-0002-0302-8645)
Institutions
- University of Pavia (IT)
- University Hospital Foundation (CA)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-04-21
- DOI
- https://doi.org/10.1093/ibd/izaf065
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05